Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
Hemogenyx Pharmaceuticals (LSE:HEMO) has announced the exercise of warrants for 67,371 new ordinary shares. The warrants, originally granted on March 11, 2025, have generated subscription monies of £235,799 for the company.
The Warrant Shares will be admitted to trading on the LSE's main market on September 10, 2025. Following admission and including the previously announced 250,000 new ordinary shares, the company's total issued shares and voting rights will increase to 5,361,267.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha comunicato l'esercizio di warrant che hanno dato diritto a 67.371 nuove azioni ordinarie. I warrant, originariamente concessi l'11 marzo 2025, hanno fruttato alla società sottoscrizioni per un totale di £235.799.
Le azioni emesse per effetto dei warrant saranno ammesse alla negoziazione sul mercato principale della LSE il 10 settembre 2025. Dopo l'ammissione e tenendo conto delle 250.000 nuove azioni ordinarie già annunciate, il numero totale di azioni emesse e i diritti di voto della società saliranno a 5.361.267.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha anunciado el ejercicio de warrants que han dado lugar a 67.371 nuevas acciones ordinarias. Los warrants, otorgados originalmente el 11 de marzo de 2025, han generado para la compañía suscripciones por valor de £235.799.
Las acciones procedentes de los warrants serán admitidas a negociación en el mercado principal de la LSE el 10 de septiembre de 2025. Tras la admisión y contando las 250.000 nuevas acciones ordinarias anunciadas previamente, el total de acciones emitidas y los derechos de voto de la compañía aumentarán a 5.361.267.
Hemogenyx Pharmaceuticals (LSE:HEMO)는 67,371주의 신규 보통주에 대한 워런트 행사가 이루어졌다고 발표했습니다. 해당 워런트는 2025년 3월 11일에 부여되었으며, 회사는 이에 대한 청약 대금으로 £235,799를 확보했습니다.
워런트로 발행된 주식은 2025년 9월 10일 LSE 메인 마켓에 상장될 예정입니다. 상장 완료 후, 그리고 이전에 발표된 250,000주의 신규 보통주를 포함하면 회사의 총 발행 주식 및 의결권 수는 5,361,267로 증가합니다.
Hemogenyx Pharmaceuticals (LSE:HEMO) a annoncé l'exercice de warrants donnant lieu à 67 371 nouvelles actions ordinaires. Les warrants, initialement attribués le 11 mars 2025, ont procuré à la société des souscriptions d'un montant de £235 799.
Les actions résultant de ces warrants seront admises aux négociations sur le marché principal de la LSE le 10 septembre 2025. Après admission et en incluant les 250 000 nouvelles actions ordinaires annoncées précédemment, le nombre total d'actions émises et les droits de vote de la société passeront à 5 361 267.
Hemogenyx Pharmaceuticals (LSE:HEMO) hat die Ausübung von Warrants bekanntgegeben, wodurch 67.371 neue Stammaktien entstanden sind. Die Warrants, die ursprünglich am 11. März 2025 gewährt wurden, haben für das Unternehmen Zeichnungsbeträge in Höhe von £235.799 eingebracht.
Die durch die Warrants ausgegebenen Aktien werden am 10. September 2025 im Hauptmarkt der LSE zum Handel zugelassen. Nach der Zulassung und einschließlich der zuvor angekündigten 250.000 neuen Stammaktien erhöht sich die Gesamtzahl der ausgegebenen Aktien und Stimmrechte des Unternehmens auf 5.361.267.
- Receipt of £235,799 in subscription monies from warrant exercise
- Successful warrant conversion indicates investor confidence
- Expansion of total shares to 5,361,267 enhances market liquidity
- Potential dilution of existing shareholders' ownership
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
LONDON, UK / ACCESS Newswire / September 5, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has received notices to exercise warrants over 67,371 new ordinary shares in the Company (the "Warrant Shares").
The Warrant Shares are being issued pursuant to the exercise of warrants granted and announced on 11 March 2025. Subscription monies of
Admission and Total Voting Rights
Application will be made for the Warrant Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 10 September 2025 ("Admission").
Upon Admission (and including the 250,000 new ordinary shares being issued as announced on 3 September 2025), the total number of issued shares and the total number of voting rights in the Company will be 5,361,267.
The above figure of 5,361,267 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Company will keep the market informed of future developments as trials proceed.
Enquiries:
Hemogenyx Pharmaceuticals plc |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
Peter Redmond, Director |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City .
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
How many warrants were exercised in Hemogenyx Pharmaceuticals' September 2025 announcement?
What is the total amount of subscription money received by Hemogenyx from the warrant exercise?
When will the new Warrant Shares begin trading on the LSE?
What will be Hemogenyx's total number of issued shares after the warrant exercise?
